BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34948154)

  • 21. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.
    Hassanein SS; Ibrahim SA; Abdel-Mawgood AL
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer.
    Yoon S; Yang H; Ryu HM; Lee E; Jo Y; Seo S; Kim D; Lee CH; Kim W; Jung KH; Park SR; Choi EK; Kim SW; Park KS; Lee DH
    Cancer Res Treat; 2022 Jul; 54(3):767-781. PubMed ID: 34607394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
    Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer.
    Palma F; Affinito A; Nuzzo S; Roscigno G; Scognamiglio I; Ingenito F; Martinez L; Franzese M; Zanfardino M; Soricelli A; Fiorelli A; Condorelli G; Quintavalle C
    Cancer Gene Ther; 2021 May; 28(5):413-426. PubMed ID: 32948832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
    Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
    Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS.
    Fan Q; Hu X; Zhang H; Wang S; Zhang H; You C; Zhang CY; Liang H; Chen X; Ba Y
    Cell Physiol Biochem; 2017; 44(4):1311-1324. PubMed ID: 29183007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in
    Mehta AK; Hua K; Whipple W; Nguyen MT; Liu CT; Haybaeck J; Weidhaas J; Settleman J; Singh A
    Sci Signal; 2017 Sep; 10(496):. PubMed ID: 28900044
    [No Abstract]   [Full Text] [Related]  

  • 34. Amplification of Wild-type
    Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
    Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in
    Chatterjee S; Huang EH; Christie I; Kurland BF; Burns TF
    Mol Cancer Ther; 2017 May; 16(5):793-804. PubMed ID: 28167505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.